Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 3/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.44 |
| ▸ | CDC25B | P30305 | 8/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410624 | 0.91 | PTPN1 (0.52) | TACR2PTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL26349698 | 0.88 | PTPN1 (0.48) | PTPN1CDC25BPTPN2PTPN6PTPN11 | |
| SCHEMBL9925398 | 0.79 | NT5E (0.49) | TACR2PTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL15982057 | 0.78 | NT5E (0.55) | TACR2PTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL14667229 | 0.78 | SSTR1 (0.44) | PTPN1CDC25BPTPN2PTPN6PTPN11 | |
| SCHEMBL26354602 | 0.77 | TACR2 (0.46) | TACR2NT5ESSTR1SSTR2SSTR4 | |
| SCHEMBL29410628 | 0.77 | PTPN1 (0.56) | PTPN1CDC25BPTPN2PTPN6PTPN11 | |
| SCHEMBL12917695 | 0.77 | LMNA (0.55) | CA1CA2CA9 | |
| SCHEMBL16076881 | 0.76 | SLC6A2 (0.48) | TACR2PTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL26349674 | 0.76 | SLC6A2 (0.48) | TACR2PTPN1CDC25BSSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303618-A1 | TRIPTOLIDE CONJUGATES AND USES THEREOF | REYOUNG CORPORATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303618-A1 | TRIPTOLIDE CONJUGATES AND USES THEREOF | TLR9, XIAP, ENPP2 | TACR2 1447/4885PTPN1 736/4885CDC25B 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.